![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/11/17/2782524/0/en/Adlai-Nortye-Announces-Completion-of-Patient-Enrollment-in-Global-Phase-III-Clinical-Trial-of-Buparlisib-AN2025-in-Combination-with-Paclitaxel-for-the-Treatment-of-Recurrent-or-Met.html
https://www.prnewswire.com/news-releases/adlai-nortyes-buparlisib-an2025-set-to-become-a-potential-treatment-for-anti-pd-1-non-responding-tumor-in-hnscc-300813063.html
https://www.reuters.com/article/us-novartis-breast-cancer/novartis-trial-win-lifts-profile-of-new-breast-cancer-drug-idUSKCN1L80PM
https://endpts.com/novartis-just-boasted-of-a-big-phiii-pi3k-success-but-heres-why-we-should-hold-our-applause-for-now/
https://pharmaphorum.com/news/novartis-success-breast-cancer-inhibitor/
https://www.prnewswire.com/news-releases/adlai-nortye-announces-the-publication-of-the-biomarker-analysis-from-beril-1-the-buparlisib-study-in-hnscc-895401608.html
https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-biogen-eisai-alzheimer-s-win-otsuka-deals-samsung-biologics-criminal
https://endpts.com/novartis-punts-a-late-stage-pi3k-drug-with-a-worrying-safety-profile-to-one-of-chinas-upstart-biotechs/
https://www.fiercebiotech.com/biotech/novartis-hands-off-buparlisib-to-china-s-adlai-noryte